GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Deferred Policy Acquisition Costs

GlycoNex (ROCO:4168) Deferred Policy Acquisition Costs


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


GlycoNex (ROCO:4168) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.